EQUITY RESEARCH MEMO

nanoTherics

Generated 5/10/2026

Executive Summary

Conviction (model self-assessment)40/100

nanoTherics is a UK-based private company that develops tools for magnetic nanoparticle heating applications, including calorimetry, in vitro and in vivo studies, and drug delivery. Founded in 2008, the company focuses on providing flexible and reliable solutions for researchers in drug delivery and neuroscience. Despite limited public information on funding or stage, nanoTherics has established a niche in the magnetic nanoparticle field, serving science professionals with practical tools for heating applications. The company's technology holds promise for advancing targeted drug delivery and hyperthermia treatments, areas with growing clinical interest. However, the lack of disclosed milestones or commercial products suggests an early-stage or steady-state operation.

Upcoming Catalysts (preview)

  • TBDNew Product Launch for In Vivo Magnetic Hyperthermia50% success
  • TBDStrategic Research Partnership with Academic Institutions40% success
  • TBDRegulatory Clearance for Drug Delivery Device20% success
Locked sections
  • · Pipeline Analysis
  • · Competitive Landscape
  • · Catalyst Calendar (full 12-month)
  • · Bull Case
  • · Bear Case
  • · Counterfactual Scenarios
  • · Valuation Notes
  • · SEC Filing Highlights
  • · Insider Activity
  • · Literature Watch
  • · Patent Landscape
  • · Mechanism Cluster Map
  • · Audio Briefing (5 min)